Nyxoah to Participate in Upcoming Investor Conferences
September 05 2023 - 4:30PM
Nyxoah to Participate in
Upcoming Investor Conferences
Mont-Saint-Guibert, Belgium –
September 5, 2023,
10:30pm CET / 4:30pm ET – Nyxoah SA (Euronext Brussels/Nasdaq:
NYXH) (“Nyxoah” or the “Company”), a medical technology
company focused on the development and commercialization of
innovative solutions to treat Obstructive Sleep Apnea (OSA), today
announced that the Company will participate in two upcoming
investor conferences in New York City.
Olivier Taelman, Nyxoah’s Chief Executive
Officer, will deliver corporate updates at the H.C. Wainwright 25th
Annual Global Investment Conference on Tuesday, September 12, 2023,
at 1:30pm EST and the Baird Global Healthcare Conference on
Wednesday, September 13, 2023, at 12:15pm EST. Webcasts of the
presentations will be available on the Events section of Nyxoah’s
Investor Relations website. The Company will also be available for
1x1 meetings with institutional investors attending the events.
Nyxoah’s Investor Presentation can be accessed
on the Shareholder Information section of the Company’s Investor
Relations page.
About NyxoahNyxoah is a medical
technology company focused on the development and commercialization
of innovative solutions to treat Obstructive Sleep Apnea (OSA).
Nyxoah’s lead solution is the Genio® system, a patient-centered,
leadless and battery-free hypoglossal neurostimulation therapy for
OSA, the world’s most common sleep disordered breathing condition
that is associated with increased mortality risk and cardiovascular
comorbidities. Nyxoah is driven by the vision that OSA patients
should enjoy restful nights and feel enabled to live their life to
its fullest.
Following the successful completion of the BLAST
OSA study, the Genio® system received its European CE Mark in 2019.
Nyxoah completed two successful IPOs: on Euronext Brussels in
September 2020 and NASDAQ in July 2021. Following the positive
outcomes of the BETTER SLEEP study, Nyxoah received CE mark
approval for the expansion of its therapeutic indications to
Complete Concentric Collapse (CCC) patients, currently
contraindicated in competitors’ therapy. Additionally, the Company
is currently conducting the DREAM IDE pivotal study for FDA and
U.S. commercialization approval.
For more information, please visit
http://www.nyxoah.com/.
Caution – CE marked since 2019.
Investigational device in the United States. Limited by U.S.
federal law to investigational use in the United States.
Contact:NyxoahDavid DeMartino,
Chief Strategy Officerdavid.demartino@nyxoah.com +1 310 310
1313
- ENGLISH_Nyxoah to Participate in HCW and Baird Conferences
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From May 2024 to Jun 2024
Nyxoah (NASDAQ:NYXH)
Historical Stock Chart
From Jun 2023 to Jun 2024